Clinical Trials

Find a Trial

Trial Summary

Protocol No.BR-076
Principal InvestigatorMiller, Kathy
PhasePhase II
Age GroupAdult
TitleA Randomized Phase II clinical trial assessing the Efficacy and Safety of MK-3475 ( pembrolizumab) in combination with carboplatin and gemcitabine in patients with metastatic triple negative breast cancer
DescriptionThe main purpose of this study is to see if Pembrolizumab in combination with chemotherapy (carboplatin and gemcitabine) is safe and effective in treating patients with metastatic triple negative breast cancer. Pembrolizumab is a drug which may help the immune system to target and destroy cancer cells. Pembrolizumab has been approved by the FDA for the treatment of advanced melanoma and metastatic non-small cell lung cancer. However, it has not been approved as a treatment for breast cancer.
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:

  • Females 18 years or older
  • Metastatic triple negative invasive breast cancer
For a full list of participation criteria, please visit
Applicable Disease SitesBreast
Participating InstitutionsIndiana University (IU)
  • Eskenazi Hospital
  • Indiana University Hospital / IU Simon Cancer Center
  • Spring Mill Medical Center
Treatment TypeTreatment
ContactPhone: (317) 278-5632